The aim of SILICOFCM project (In Silico trials for drug tracing the effects of sarcomeric protein mutations leading to familial cardiomyopathy) is to develop a computational platform for in silico clinical trials of FCMs that would take into consideration comprehensive list of patient specific features (genetic, biological, pharmacologic, clinical, imaging and patient specific cellular aspects) capable of optimizing and testing medical treatment strategy with the purpose of maximizing positive therapeutic outcome, avoiding adverse effects, avoiding drug interactions, preventing sudden cardiac death, shortening time between the drug treatment commencement and the desired result. The SILICOFCM is a multi-modular, innovative in silico clinical trials solution for the design and functional optimization of whole heart performance and monitoring effectiveness of pharmacological treatment, with aim to reduce the animal studies and the human clinical trials. The SILICOFCM platform is based on the integrated multidisciplinary and multiscale methods for analysis of patient-specific data and development of patient-specific models for monitoring and assessment of patient condition from current through the progression of disease.